Gynecomastia
Gynecomastia is the benign enlargement of glandular breast tissue in males, resulting from an imbalance between estrogen and androgen action at the breast tissue level. It is the most common breast condition in men and boys, affecting up to 70% of adolescent males during puberty and a significant proportion of older men — yet it remains widely misunderstood, underinvestigated, and undertreated.
Gynecomastia is not simply fat accumulation in the chest — a distinction that matters both clinically and for the patient. True gynecomastia involves the proliferation of ductal and stromal breast tissue driven by estrogenic stimulation, producing a firm, disc-like mass of glandular tissue beneath the nipple that is distinct from the soft, diffuse adipose tissue seen in pseudogynecomastia (lipomastia).
While gynecomastia is benign, it can be a sign of an underlying hormonal disorder, systemic disease, medication effect, or — rarely — malignancy. A thorough evaluation is always warranted when gynecomastia is newly detected or unexplained, particularly in adult men.
The Hormonal Basis of Gynecomastia
Male breast tissue, like female breast tissue, is sensitive to estrogen. Under normal physiological conditions, the high ratio of androgens (primarily testosterone) to estrogens keeps male breast tissue quiescent. Gynecomastia develops when this ratio shifts — either because estrogen levels rise, androgen levels fall, androgen receptor sensitivity is reduced, or breast tissue becomes abnormally sensitive to normal estrogen levels.
The key mechanism is relative or absolute estrogen excess at the tissue level. This can occur through several pathways:
- Increased estrogen production — from testicular or adrenal tumors secreting estrogen, or from increased peripheral aromatization of androgens to estrogens (particularly in obesity, liver disease, or hyperthyroidism)
- Decreased testosterone production — in hypogonadism of any cause, the androgen-to-estrogen ratio falls even if absolute estrogen levels are normal
- Increased SHBG — sex hormone-binding globulin binds testosterone more avidly than estradiol, reducing free testosterone relative to free estrogen
- Estrogen-like drug effects — many medications directly stimulate estrogen receptors or alter androgen-estrogen balance
- Androgen receptor defects — rare genetic conditions in which androgen receptors function abnormally
Types and Causes of Gynecomastia
Physiological gynecomastia
Gynecomastia occurring at predictable life stages due to normal hormonal shifts is considered physiological. It typically resolves without treatment.
- Neonatal gynecomastia — affects approximately 60–90% of newborn boys due to transplacental transfer of maternal estrogens; resolves within weeks
- Pubertal gynecomastia — the most common form; affects 50–70% of adolescent boys during the mid-pubertal surge, typically between ages 10–14, when estradiol rises before testosterone reaches adult levels. Usually resolves within 6–24 months. Persistence beyond age 17 warrants evaluation.
- Age-related (senescent) gynecomastia — common in men over 50, driven by declining testosterone production, increased peripheral aromatization due to rising body fat, and increased SHBG with aging
Pathological gynecomastia
Gynecomastia outside of physiological windows, or that is unexplained, painful, rapidly enlarging, or unilateral, warrants investigation for an underlying cause.
Hormonal causes
- Hypogonadism (primary or secondary) — low testosterone from any cause; includes Klinefelter syndrome (47,XXY), the most common genetic cause of hypogonadism and a recognized cause of gynecomastia
- Hyperprolactinemia — elevated prolactin suppresses LH and FSH, reducing testosterone production
- Hyperthyroidism — increases SHBG and peripheral aromatization, raising estrogen relative to free testosterone
- Adrenal tumors — may secrete androstenedione or estrogens directly
- Testicular tumors — Leydig cell tumors and germ cell tumors can secrete estrogens or hCG (which stimulates estrogen production); gynecomastia as a presenting sign of testicular cancer is well recognized
- hCG-secreting tumors — including non-testicular germ cell tumors and lung carcinomas; hCG stimulates testicular estrogen production
Systemic disease
- Liver disease / cirrhosis — impairs estrogen metabolism and increases SHBG, producing relative estrogen excess
- Chronic kidney disease — causes hypogonadism through multiple mechanisms
- Malnutrition and refeeding — refeeding after starvation causes a transient hormonal surge that can trigger gynecomastia
- Hyperthyroidism — increases peripheral aromatization
- HIV/AIDS — directly and via antiretroviral medications
Medication-induced gynecomastia
Medications are one of the most common causes of gynecomastia in adults. Any new gynecomastia in an adult man should prompt a thorough medication review.
| Drug class | Examples | Mechanism |
|---|---|---|
| Antiandrogens / prostate therapy | Bicalutamide, flutamide, enzalutamide, spironolactone, finasteride | Block androgen receptors or reduce androgen production |
| GnRH agonists / androgen deprivation | Leuprolide, goserelin | Suppress testosterone production; used in prostate cancer |
| Anabolic steroids / androgens | Testosterone (exogenous), nandrolone, DHEA | Aromatize to estradiol; suppress endogenous testosterone on cessation |
| Antipsychotics | Haloperidol, risperidone, olanzapine | Elevate prolactin, suppressing testosterone |
| Antidepressants | Some SSRIs, tricyclics | Various; some may elevate prolactin |
| H2 blockers | Cimetidine (less so ranitidine) | Antiandrogenic effects |
| Cardiovascular drugs | Digoxin, spironolactone, amiodarone, calcium channel blockers | Various — estrogenic or antiandrogenic |
| Proton pump inhibitors | Omeprazole (rarely) | Possible antiandrogenic effects at high doses |
| Opioids | Chronic opioid therapy | Suppresses hypothalamic-pituitary-gonadal axis |
| Substances of abuse | Cannabis, alcohol, heroin, amphetamines | Various hormonal effects |
| Chemotherapy agents | Alkylating agents | Testicular damage causing hypogonadism |
Testosterone replacement therapy (TRT) deserves specific mention. Exogenous testosterone aromatizes to estradiol — and if the resulting estradiol level is not adequately monitored and managed, gynecomastia is a common complication. Men on TRT should have regular estradiol monitoring.
Gynecomastia vs. Pseudogynecomastia
A critical clinical distinction that drives both diagnosis and management:
| Feature | True Gynecomastia | Pseudogynecomastia (Lipomastia) |
|---|---|---|
| Tissue type | Glandular breast tissue | Adipose (fat) tissue only |
| Feel on palpation | Firm, rubbery disc beneath nipple | Soft, diffuse; no central disc |
| Hormone-driven | Yes | No — related to overall body fat |
| Responds to hormonal treatment | Sometimes (if early/active) | No |
| Associated with systemic disease | Can be | Rarely |
| Requires hormonal workup | Yes | Generally not |
On physical examination, true gynecomastia produces a firm, concentric, rubbery subareolar disc that moves with the nipple-areolar complex when the chest is compressed. Pseudogynecomastia has no central disc — just diffuse, soft adipose tissue. Imaging (ultrasound or mammography) can confirm the distinction when examination is inconclusive.
Symptoms and Presentation
- Visible breast enlargement — unilateral or bilateral; bilateral is more common in physiological and drug-induced causes
- Breast tenderness or sensitivity — particularly in active, early-stage gynecomastia
- A palpable firm disc of tissue beneath one or both nipples
- Nipple discharge — uncommon; when present, warrants evaluation for prolactinoma or malignancy
Pain and tenderness reflect active glandular proliferation and are more common in early or recent-onset gynecomastia. Long-standing gynecomastia tends to be painless as the active proliferative phase gives way to fibrosis.
Features that warrant urgent evaluation for malignancy:
- Hard, irregular, or fixed breast mass
- Eccentric position (not centered under the nipple)
- Unilateral with skin changes, nipple retraction, or bloody discharge
- Associated lymphadenopathy
Male breast cancer accounts for less than 1% of all breast cancers but must be excluded, particularly in older men with new unilateral breast enlargement.
Diagnosis and Laboratory Evaluation
The clinical history and physical examination guide the extent of workup. In adolescents with classic pubertal gynecomastia and no concerning features, extensive testing is not required. In adult men with unexplained, recent-onset, or progressive gynecomastia, a structured hormonal and metabolic evaluation is essential.
Recommended lab panel
| Marker | Role | What to look for |
|---|---|---|
| Total testosterone | Assess androgen status | Low in hypogonadism |
| Free testosterone | Bioavailable androgen | Low when SHBG is elevated |
| Estradiol (E2) | Primary estrogen; key ratio marker | Elevated in estrogen-secreting tumors, obesity, liver disease, TRT |
| LH and FSH | Distinguish primary from secondary hypogonadism | High in primary (testicular) hypogonadism; low/normal in secondary (pituitary) |
| Prolactin | Screen for prolactinoma or drug-induced hyperprolactinemia | Elevated in prolactinoma, antipsychotics, dopamine-depleting drugs |
| SHBG | Affects free testosterone availability | Elevated in liver disease, hyperthyroidism, aging — reduces free testosterone |
| hCG (beta-hCG) | Screen for hCG-secreting tumors | Elevated in testicular germ cell tumors, other hCG-secreting malignancies |
| TSH | Screen for hyperthyroidism | Suppressed in hyperthyroidism (increases aromatization and SHBG) |
| Liver function tests (ALT, AST, ALP, bilirubin) | Screen for liver disease | Abnormal in cirrhosis or significant liver dysfunction |
| Renal function (creatinine, eGFR) | Screen for chronic kidney disease | Elevated creatinine in renal-associated hypogonadism |
| DHEA-S | Adrenal androgen; screen for adrenal tumor | Very elevated in adrenocortical carcinoma |
Testicular ultrasound is indicated when hCG is elevated, when a testicular abnormality is palpated, or when the clinical picture suggests a testicular source. Imaging (ultrasound or mammogram) of the breast itself is indicated when malignancy cannot be excluded clinically.
Treatment of Gynecomastia
Treatment depends on the cause, duration, degree of tissue fibrosis, and patient preference.
Treat the underlying cause first
When gynecomastia is driven by an identifiable and treatable cause — medication, hypogonadism, hyperprolactinemia, hyperthyroidism, or liver disease — addressing that cause is the priority. Early gynecomastia (within the first 6–12 months, before significant fibrosis develops) may resolve with successful treatment of the underlying condition.
Watchful waiting
Pubertal gynecomastia typically resolves spontaneously within 6–24 months and requires only reassurance and monitoring. If it has not improved after 2 years, or if it is causing significant psychological distress, intervention may be considered.
Medical treatment
Medical therapy is most effective in early, active gynecomastia — before fibrosis establishes. It is generally ineffective in long-standing cases.
- Selective estrogen receptor modulators (SERMs) — tamoxifen and raloxifene block estrogen receptors in breast tissue; tamoxifen is most commonly used and is effective in reducing breast volume and pain in active gynecomastia
- Aromatase inhibitors (anastrozole, letrozole) — reduce conversion of testosterone to estradiol; evidence is more modest than for SERMs but may be useful in specific cases (e.g., men on TRT with elevated estradiol)
Surgery
Surgical correction (subcutaneous mastectomy, often combined with liposuction) is the definitive treatment and is indicated when gynecomastia is long-standing (with established fibrosis), severe, or causing significant psychological distress. Surgery is not affected by hormone status or duration and is highly effective with good aesthetic outcomes in experienced hands.
Gynecomastia in Men on Testosterone Replacement Therapy (TRT)
This is one of the most clinically relevant and frequently encountered contexts for gynecomastia in modern practice. Exogenous testosterone aromatizes to estradiol via the aromatase enzyme — particularly in men with higher body fat. If estradiol rises above approximately 40–50 pg/mL (147–184 pmol/L) without adequate free testosterone to balance it, gynecomastia can develop.
Prevention and management in TRT patients involves:
- Regular monitoring of estradiol (using the ultrasensitive LC/MS assay for accuracy) alongside testosterone and SHBG
- Dose adjustment if testosterone is being converted excessively to estradiol
- Careful, judicious use of aromatase inhibitors — under-dosing estradiol is as harmful as over-dosing, carrying risks of bone loss, low libido, joint pain, and mood disturbance
- Weight management — adipose tissue is the primary site of aromatization in men
Summary
Gynecomastia is the benign enlargement of glandular breast tissue in males, driven by a relative excess of estrogen action over androgen action at breast tissue receptors. It is common — affecting up to 70% of adolescent boys at some point during puberty and a significant proportion of older men — and has a wide range of causes spanning physiological hormonal transitions, medications, systemic disease, and rarely, hormone-secreting tumors.
Distinguishing true gynecomastia from pseudogynecomastia (fat accumulation) is the first clinical step and determines the need for hormonal evaluation. A structured lab workup — including testosterone, estradiol, LH, FSH, prolactin, SHBG, hCG, TSH, and liver and renal function — identifies the underlying cause in the majority of pathological cases and guides targeted treatment.
Treatment is most effective when the underlying cause is identified and addressed early, before fibrosis establishes. Long-standing gynecomastia with fibrosis responds poorly to medical therapy and typically requires surgical correction. Regular hormonal monitoring — particularly in men on testosterone therapy — is the most effective prevention strategy.
FAQ: Gynecomastia
What is gynecomastia?
Gynecomastia is the benign enlargement of glandular breast tissue in males, caused by a relative excess of estrogen over androgen activity at the breast tissue level. It is not fat accumulation — it is true proliferation of ductal and stromal breast tissue. It is the most common breast condition in men and boys, affecting up to 70% of adolescent males during puberty and a significant proportion of older men.
What causes gynecomastia?
Gynecomastia results from any condition that shifts the balance between estrogen and androgen action toward relative estrogen excess. Common causes include physiological hormonal changes (puberty, aging), hypogonadism (low testosterone), medications (especially antiandrogens, anabolic steroids, antipsychotics, and spironolactone), obesity (which increases aromatization of androgens to estrogens), liver disease, hyperthyroidism, hyperprolactinemia, and — rarely — estrogen-secreting or hCG-secreting tumors.
What is the difference between gynecomastia and pseudogynecomastia?
True gynecomastia involves the enlargement of glandular breast tissue — felt as a firm, rubbery disc centered beneath the nipple. Pseudogynecomastia (lipomastia) is chest enlargement due to fat accumulation only, without glandular tissue proliferation. The distinction matters because true gynecomastia warrants hormonal investigation and may respond to medical or surgical treatment, while pseudogynecomastia is managed primarily through weight loss and does not require hormonal workup.
What blood tests are done for gynecomastia?
A standard workup includes total and free testosterone, estradiol, LH, FSH, prolactin, SHBG, beta-hCG, TSH, liver function tests, and renal function. These tests assess androgen and estrogen levels, distinguish primary from secondary hypogonadism, screen for prolactinoma, identify liver or kidney disease, detect hyperthyroidism, and — critically — screen for hCG-secreting tumors including testicular cancer. Testicular ultrasound is indicated when hCG is elevated or a testicular abnormality is suspected.
Does high estradiol cause gynecomastia in men?
Elevated estradiol relative to testosterone is a key driver of gynecomastia in men. Absolute estradiol levels matter less than the ratio — gynecomastia can occur even with modestly elevated estradiol if testosterone is simultaneously low or if SHBG is elevated (reducing free testosterone). Men on testosterone replacement therapy are at particular risk if estradiol rises without adequate monitoring, because exogenous testosterone aromatizes to estradiol — especially in men with higher body fat.
Can gynecomastia be a sign of cancer?
Gynecomastia itself is benign, but it can occasionally be a presenting sign of an underlying malignancy — particularly testicular germ cell tumors (which may secrete hCG, stimulating estrogen production) or, rarely, hCG-secreting non-testicular tumors. Male breast cancer is rare (less than 1% of all breast cancers) but must be excluded in adult men with new unilateral breast enlargement, especially if the mass is hard, irregular, or eccentric. A beta-hCG measurement and, where indicated, testicular ultrasound are essential in the workup.
Does gynecomastia go away on its own?
Pubertal gynecomastia — the most common form — typically resolves spontaneously within 6–24 months as testosterone rises and the androgen-to-estrogen ratio normalizes. Gynecomastia caused by a drug or reversible condition often improves or resolves when the cause is removed, provided it is addressed before fibrosis develops (within approximately 6–12 months of onset). Long-standing gynecomastia with established fibrosis does not resolve spontaneously and does not respond well to medical therapy — surgery is the effective option at that stage.
How is gynecomastia treated?
Treatment depends on the cause, duration, and degree of tissue fibrosis. The first step is identifying and addressing the underlying cause (stopping the offending medication, treating hypogonadism, etc.). In early, active gynecomastia without significant fibrosis, tamoxifen (a selective estrogen receptor modulator) is the most effective medical treatment. Aromatase inhibitors may be useful in specific contexts. In long-standing gynecomastia with fibrosis, or when significant distress is present, surgical correction (subcutaneous mastectomy with or without liposuction) is the definitive treatment.
Can testosterone therapy cause gynecomastia?
Yes. Exogenous testosterone is converted (aromatized) to estradiol, particularly in men with higher body fat. If estradiol rises significantly — typically above approximately 40–50 pg/mL — without sufficient testosterone to maintain the androgen-to-estrogen balance, gynecomastia can develop. This is why estradiol monitoring is an essential part of TRT management. Prevention involves regular estradiol testing (using the ultrasensitive LC/MS assay), appropriate dose management, and weight control. If needed, judicious use of an aromatase inhibitor under medical supervision can reduce estradiol — but over-suppression of estradiol carries its own risks.
What role does SHBG play in gynecomastia?
SHBG (sex hormone-binding globulin) binds sex hormones in the blood, making them biologically inactive. Crucially, SHBG binds testosterone more avidly than estradiol — so when SHBG is elevated (as occurs with aging, liver disease, hyperthyroidism, and some medications), free testosterone falls proportionally more than free estradiol. This shifts the effective androgen-to-estrogen ratio toward relative estrogen excess at the tissue level, even when total testosterone appears normal. Measuring SHBG alongside testosterone and estradiol provides a more complete hormonal picture.
Is gynecomastia associated with Klinefelter syndrome?
Yes. Klinefelter syndrome (47,XXY karyotype) is the most common chromosomal cause of male hypogonadism and a recognized cause of gynecomastia. Men with Klinefelter syndrome have testicular failure with low testosterone, elevated LH and FSH, and a higher ratio of estrogen to androgen — making gynecomastia common. Klinefelter syndrome is also associated with increased risk of male breast cancer, making gynecomastia in this population require particularly careful evaluation.
Show more